Acurx Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Acurx Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Acurx Pharmaceuticals Inc recorded a cumulative net loss of $-8 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -87.36%.

However, within the Healthcare sector 709 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4264, from total ROA ranking in the first quarter of 2026 at 5032.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	79.2 %	98.52 %	99.32 %	2.05 %	-6.42 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-8	-7	-8	-9	-10
Return On Assets (TTM)	-87.36 %	-101.7 %	-128.71 %	-175.28 %	-192.25 %
ACXP's Total Ranking	# 4264	# 5032	# 4565	# 4665	# 4770
Total Assets (TTM) in million	11	10	8	6	6
Seq. Total Assets Change	15.67 %	24.06 %	25.95 %	-0.85 %	28.14 %
Seq. Net Income Change	-	-	-	-	-

ACXP's 5 Years Annual ROA >> Back to ACXP Management Effectiveness >> Compare ACXP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 325
Sector	# 710
Overall	# 4163

Return On Assets Statistics
High	Average	Low
-87.49 %	-152.96 %	-223.76 %
(Jun 30 2026)		(Mar 31 2025)

Financial Statements
Acurx Pharmaceuticals Inc 's Assets	$ 11 million	ACXP's Balance sheet
Acurx Pharmaceuticals Inc 's Income	$ -2 million	Quarterly ACXP's Income Statement
ACXP's Income by Division		See ACXP's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	99.32 %	-49.96 %	-17.78 %	-29.25 %	-
Total Assets in million	8	4	8	9	13
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-8	-14	-15	-12	-13
Annual Return On Assets	-103.6 %	-365.56 %	-189.1 %	-128.97 %	-96.18 %

ACXP's 5 Years Annual ROA >> Back to ACXP Management Effectiveness >> Compare ACXP ROA to its Competitors

More Return On Assets Ratios
ACXP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ACXP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ACXP's Competitors
Subscribers only: Roa for Acurx Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for ACXP's Customers

You may also want to know
ACXP's Roi	ACXP's Inventory Turnover Ratio	ACXP's Growth Rates	ACXP's Dividend Comparisons
	ACXP's Profitability Ratios	ACXP's Asset Turnover Ratio	ACXP's Dividend Growth
ACXP's Roe	ACXP's Valuation Ratios	ACXP's Financial Strength Ratios	ACXP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-03T06:20:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.